ECSP22080683A - 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52 - Google Patents

3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52

Info

Publication number
ECSP22080683A
ECSP22080683A ECSENADI202280683A ECDI202280683A ECSP22080683A EC SP22080683 A ECSP22080683 A EC SP22080683A EC SENADI202280683 A ECSENADI202280683 A EC SENADI202280683A EC DI202280683 A ECDI202280683 A EC DI202280683A EC SP22080683 A ECSP22080683 A EC SP22080683A
Authority
EC
Ecuador
Prior art keywords
pyrazines
substituted
phenoxyazetidine
agonist activity
phenoxyazetidin
Prior art date
Application number
ECSENADI202280683A
Other languages
English (en)
Inventor
Marco Ferrara
Graeme Semple
Giacomo Fossati
Ursula Mueller-Vieira
Kai Gerlach
Scott Hobson
Julian Wippich
Yifeng Xiong
Uta Friederike Lessel
Frank Runge
Barbara Bertani
Original Assignee
Boehringer Ingelheim Int
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Arena Pharm Inc filed Critical Boehringer Ingelheim Int
Publication of ECSP22080683A publication Critical patent/ECSP22080683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a 3-fenoxiazetidin-1-il-pirazinas sustituidas de la fórmula general (I) que son agonistas de GPR52, útiles en el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. Además, la invención se refiere a 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) para su uso como medicamento, composiciones farmacéuticas que comprenden 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) y procesos para preparar composiciones farmacéuticas, así como procesos para fabricar los compuestos según la invención.
ECSENADI202280683A 2020-03-30 2022-10-18 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52 ECSP22080683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
ECSP22080683A true ECSP22080683A (es) 2022-11-30

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202280683A ECSP22080683A (es) 2020-03-30 2022-10-18 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52

Country Status (20)

Country Link
US (1) US11780827B2 (es)
EP (1) EP4126850B1 (es)
JP (1) JP7617134B2 (es)
KR (1) KR20220161454A (es)
CN (1) CN115697997B (es)
AR (1) AR121675A1 (es)
AU (1) AU2021250303A1 (es)
BR (1) BR112022018996A2 (es)
CA (1) CA3176265A1 (es)
CO (1) CO2022014886A2 (es)
CR (1) CR20220554A (es)
DO (1) DOP2022000203A (es)
EC (1) ECSP22080683A (es)
IL (1) IL296823A (es)
JO (1) JOP20220235A1 (es)
MX (1) MX2022012067A (es)
PE (1) PE20221918A1 (es)
PH (1) PH12022552553A1 (es)
TW (1) TW202204343A (es)
WO (1) WO2021198149A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN117940420A (zh) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272633T1 (de) * 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
CN108174603B (zh) * 2015-04-29 2021-07-02 阿芮纳制药有限公司 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺
JP2018531926A (ja) * 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法

Also Published As

Publication number Publication date
BR112022018996A2 (pt) 2022-11-01
TW202204343A (zh) 2022-02-01
CN115697997B (zh) 2024-07-30
US11780827B2 (en) 2023-10-10
CO2022014886A2 (es) 2022-10-31
DOP2022000203A (es) 2022-11-30
JOP20220235A1 (ar) 2022-09-28
AU2021250303A1 (en) 2022-09-22
JP2023522307A (ja) 2023-05-30
EP4126850A1 (en) 2023-02-08
KR20220161454A (ko) 2022-12-06
WO2021198149A1 (en) 2021-10-07
CA3176265A1 (en) 2021-10-07
PE20221918A1 (es) 2022-12-29
CR20220554A (es) 2023-01-09
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
IL296823A (en) 2022-11-01
PH12022552553A1 (en) 2024-01-03
MX2022012067A (es) 2022-10-13
US20220356172A1 (en) 2022-11-10
CN115697997A (zh) 2023-02-03
JP7617134B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
CR20210552A (es) Inhibidores del inflamasoma nlrp3
ECSP24014832A (es) Inhibidores de nlrp3
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CL2017002650A1 (es) Compuestos novedosos
CO6300957A2 (es) Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
CU20130033A7 (es) Imidazopiridazinas sustituidas
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
AR123685A1 (es) Antagonistas del mrgx2
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2022008313A2 (es) Compuestos químicos
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
DOP2024000165A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
UY30699A1 (es) Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CU20100249A7 (es) Derivados de benzoxazinona que actúan como agonistas de receptores adrenérgcos beta2 para el tratamiento de trastornos respiratorios